相关实验视频

Updated: Sep 9, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

通过附带致死性重用mercaptopurine治疗体质RB1-NUDT15的癌症

Tao Zhou^1,2, Huayun Yan², Dandan Yin²

¹Department of Laboratory Medicine/Research Centre of Clinical Laboratory Medicine West China Hospital Sichuan University Chengdu Sichuan China.

|September 4, 2025

概括

在瘤中失去视网膜母细胞瘤1 (RB1) 和努迪克斯酶15 (NUDT15) 会造成脆弱性. 这一发现支持将mercaptopurine用于RB1缺陷瘤患者的精确癌症治疗.

科学领域:

癌症学
癌症遗传学
药理学

背景情况:

在治疗不耐药的癌症,如割抵抗性前列腺癌 (CRPC) 中,体内视网膜细胞瘤1 (RB1) 损失很常见.
RB1不是直接使用药物的目标,因此需要替代治疗策略.
努迪克斯酶15 (NUDT15) 缺乏与氨酸毒性有关.

研究的目的:

研究RB1与NUDT15在癌症发展和治疗中的联系.
为了探索修素的潜在用途,如mercaptopurine,对于RB1缺乏的瘤.
确定RB1和NUDT15的共同损失所带来的漏洞.

主要方法:

对基因共删除和共沉默模式的分析.
在大量和单细胞水平上对RB1和NUDT15表达的相关性分析.
在癌症细胞系和异种移植模型中评估囊素敏感性.

主要成果:

在临床CRPC样本中观察到RB1和NUDT15的共同损失.
在543个癌细胞系中发现了RB1/ NUDT15性得分与默卡普图林敏感性的正相关性.
通过抑制细胞循环和增加细胞亡,NUDT15 knockdown使癌细胞对默卡普素敏感,而不会在体内引起白血病.

结论:

在精确的默卡普图林治疗中,RB1和NUDT15的共同损失具有可针对性的脆弱性.
对于RB1缺陷瘤的分层患者群体,可以利用与mercaptopurine一样的thiopurines的药物重定位.
这项研究阐明了瘤学中的附带致死性和精确治疗策略的分子基础.

关键词:

时间表:一个RB1 附带死亡率删除副本编号药物重新使用甲基氨酸

更多相关视频

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...